Condition: Locally Advanced (Unresectable) or Metastatic Solid Tumors · Sponsor: NEOK Bio, Inc.
This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
This description comes directly from the study's public registry record.
Willie J Hudson, MS · 615-507-4263 · whudson@neokbio.com
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| NEXT Oncology | Austin, Texas, United States | Not Yet Recruiting |
| NEXT Oncology | Dallas, Texas, United States | Not Yet Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Not Yet Recruiting |
| NEXT Oncology | Houston, Texas, United States | Not Yet Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07612176